当前位置: 首页 >> 检索结果
共有 38771 条符合本次的查询结果, 用时 3.6700723 秒

1221. Response.

作者: Charles Hatt.;Jonathan H Chung.;Justin M Oldham.
来源: Chest. 2024年165卷3期e89-e90页

1222. Be Careful About Metrics When Imbalanced Data Is Used for a Deep Learning Model.

作者: Takuma Usuzaki.;Kengo Takahashi.;Ryusei Inamori.
来源: Chest. 2024年165卷3期e87-e89页

1223. Response.

作者: Lisa Hessels.;Wim G Boersma.
来源: Chest. 2024年165卷3期e86页

1224. Potential of Muscle Mass Evaluation for Prognostic Prediction of COVID-19.

作者: Shota Yamamoto.;Chikamasa Ichita.
来源: Chest. 2024年165卷3期e86-e87页

1225. Generalizing the Use of a Procalcitonin-Guided Antibiotic Algorithm to a New Era of SARS-CoV-2 Infection.

作者: Morgan K Walker.;Sameer S Kadri.
来源: Chest. 2024年165卷3期e85-e86页

1226. A Case of Persistent Lung Masses After Treatment of Hodgkin Lymphoma.

作者: Tejas Sinha.;Jian Fu.;Ashish Bains.;Andrew Gangemi.
来源: Chest. 2024年165卷3期e79-e84页
The patient is a 49-year-old woman who had never used tobacco with a history of relapsing polychondritis and episcleritis. She sought treatment at our clinic for evaluation of multiple lung masses. She originally received a diagnosis by chest radiography performed to rule out sarcoidosis as the cause of episcleritis showing an abnormal findings. She had no contributory surgical, family, or social history. The autoimmune markers were notable for positive rheumatoid factor (153 IU/mL) and elevated erythrocyte sedimentation rate (97 mm/h) and C-reactive protein (65.5 mg/L). Pertinent studies with negative results included antineutrophilic cytoplasmic antibody, antinuclear antibody, cyclic citrullinated peptide antibody, Sjogren syndrome-related antigen A, and Sjogren syndrome-related antigen B tests.

1227. A 34-Year-Old Man With Shortness of Breath 1 Week After Having Arm Numbness.

作者: Tahir Ahmad.;Stephen J Forest.;Maneesha Bangar.;Lewis A Eisen.
来源: Chest. 2024年165卷3期e75-e78页

1228. Late-Onset Diffuse Lung Disease in an 8-Year-Old Girl.

作者: Huiying Wang.;Yu Tang.;Yuelin Shen.
来源: Chest. 2024年165卷3期e71-e74页
An 8-year-old girl presented with a 34-day history of cough, fatigue, and impaired exercise tolerance. She experienced cyanosis on exertion but denied fever, hemoptysis, hematuria, or seizures. Her perinatal and family histories were unremarkable, and she had no history of exposure to TB. A chest radiogram from a local clinic showed diffuse pulmonary lesions. Tuberculin skin test, interferon-γ release assay, and HIV antibody test results were all negative. Immunoglobulin levels and lymphocyte subsets were normal. The patient did not respond to IV azithromycin for 1 week for community-acquired pneumonia. She was transferred to our hospital because of progressive respiratory distress and hypoxemia.

1229. A 49-Year-Old Man With Fever and Dyspnea After Endobronchial Ultrasound-Guided Transbronchial Fine Needle Aspiration Biopsy.

作者: Zenglin Liao.;Hao Wang.;Jing An.;Jiajia Dong.;Xiaoyu Long.
来源: Chest. 2024年165卷3期e65-e69页
A 49-year-old man, a farmer, had been experiencing coughing, phlegm, and difficulty breathing for 2 months. He underwent a CT scan at a local hospital that showed a mediastinal mass. Bronchoscopy showed no obstruction in the tracheal lumen, and an endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TBNA) biopsy was performed on the mediastinal mass. The cytologic smear of the mediastinal mass showed a few atypical epithelial cells; the possibility of a tumor could not be ruled out. The patient visited our thoracic surgery outpatient department; based on the advice of the thoracic surgeon, the patient underwent another endobronchial ultrasound-guided transbronchial fine needle aspiration biopsy of the mediastinal mass 4 days before this admission. The patient went home and waited for the results. Two days later, the patient experienced a fever and palpitations accompanied by chills, yellow phlegm, and orthopnea. The patient visited our ED, underwent tracheal intubation, and was admitted to our ICU. The patient had had occasional coughing and phlegm for the past 10 years, which were not taken seriously or investigated. The patient does not smoke or drink alcohol, and there is no history of cancer in the family.

1230. Corrigendum to: CHEST. 2023;164(4):875-884.

来源: Chest. 2024年165卷3期754页

1231. Managing Pulmonary Arterial Hypertension With Cardiopulmonary Comorbidities.

作者: Steeve Provencher.;Vicky Mai.;Sebastien Bonnet.
来源: Chest. 2024年165卷3期682-691页
Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with left-sided heart and lung diseases are most commonly easily discriminated and treated accordingly. With the changing epidemiology of PAH, however, a growing proportion of patients at the time of diagnosis present with comorbidities of varying severity. In addition to classical PAH, two distinct phenotypes have emerged: a heart failure with preserved ejection fraction-like phenotype and a lung phenotype. Importantly, the evidence supporting the currently proposed treatment algorithm for PAH has been generated mainly from PAH trials in which patients with cardiopulmonary comorbidities have been underrepresented or excluded. As a consequence, the best therapeutic approach for patients with common PAH with cardiopulmonary comorbidities remains largely unknown and requires further investigation. The present article reviews the relevant literature on the topic and describes the authors' views on the current therapeutic approach for these patients.

1232. Precision Solutions: A Strategy to Improve Medical Care for Patients With Pulmonary Hypertension in Latin America.

作者: Mauricio Orozco-Levi.;Vinicio de Jesús Pérez.
来源: Chest. 2024年165卷3期669-672页

1233. Climate Change and Inhaler Selection in Patients With Respiratory Disease.

作者: Samir Gupta.;Simon Couillard.;Geneviève Digby.;Sze Man Tse.;Samantha Green.;Erika Penz.
来源: Chest. 2024年165卷3期503-506页

1234. Cardiorespiratory Multimorbidity in People Living With Chronic Lung Disease: Challenges, Opportunities, and a Concept for Optimization via an Integrated Care Approach.

作者: Freddy Frost.;Gregory Y H Lip.
来源: Chest. 2024年165卷3期500-502页

1235. Rebuttal From Dr Sahay.

作者: Sandeep Sahay.
来源: Chest. 2024年165卷3期498-499页

1236. Rebuttal From Drs Weatherald and Sitbon.

作者: Jason Weatherald.;Olivier Sitbon.
来源: Chest. 2024年165卷3期496-498页

1237. Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No.

作者: Sandeep Sahay.
来源: Chest. 2024年165卷3期494-496页

1238. POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.

作者: Jason Weatherald.;Olivier Sitbon.
来源: Chest. 2024年165卷3期492-494页

1239. Development and Revision of Meaningful Stage Descriptors for M1a Non-Small Cell Lung Cancer.

作者: David E Ost.
来源: Chest. 2024年165卷3期490-491页

1240. Planting the Seeds for Lung Cancer Screening Starts With Knowledge Holders.

作者: Anne C Melzer.;Abbie Begnaud.
来源: Chest. 2024年165卷3期488-489页
共有 38771 条符合本次的查询结果, 用时 3.6700723 秒